Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 38

1.

Novel Contribution of Secreted Amyloid-β Precursor Protein to White Matter Brain Enlargement in Autism Spectrum Disorder.

Sokol DK, Maloney B, Westmark CJ, Lahiri DK.

Front Psychiatry. 2019 Apr 10;10:165. doi: 10.3389/fpsyt.2019.00165. eCollection 2019. Review.

2.

Preparation of Synaptoneurosomes for the Study of Glutamate Receptor Function.

Westmark CJ, Westmark PR.

Methods Mol Biol. 2019;1941:189-197. doi: 10.1007/978-1-4939-9077-1_13.

PMID:
30707435
3.

Fragile X and APP: a Decade in Review, a Vision for the Future.

Westmark CJ.

Mol Neurobiol. 2019 Jun;56(6):3904-3921. doi: 10.1007/s12035-018-1344-x. Epub 2018 Sep 17. Review.

PMID:
30225775
4.

Rescue of Fmr1KO phenotypes with mGluR5 inhibitors: MRZ-8456 versus AFQ-056.

Westmark PR, Dekundy A, Gravius A, Danysz W, Westmark CJ.

Neurobiol Dis. 2018 Nov;119:190-198. doi: 10.1016/j.nbd.2018.08.008. Epub 2018 Aug 17.

PMID:
30125640
5.

A Role for Amino Acid Balance in Dietary Treatments for Epilepsy.

Westmark CJ.

J Nutr. 2018 Mar 1;148(3):307-308. doi: 10.1093/jn/nxx044. No abstract available.

PMID:
29546299
6.

Commentary: Depletion of the Fragile X Mental Retardation Protein in Embryonic Stem Cells Alters the Kinetics of Neurogenesis.

Westmark CJ.

Front Mol Neurosci. 2017 Feb 7;10:29. doi: 10.3389/fnmol.2017.00029. eCollection 2017. No abstract available.

7.

Soy-Based Therapeutic Baby Formulas: Testable Hypotheses Regarding the Pros and Cons.

Westmark CJ.

Front Nutr. 2017 Jan 18;3:59. doi: 10.3389/fnut.2016.00059. eCollection 2016.

8.

APP Causes Hyperexcitability in Fragile X Mice.

Westmark CJ, Chuang SC, Hays SA, Filon MJ, Ray BC, Westmark PR, Gibson JR, Huber KM, Wong RK.

Front Mol Neurosci. 2016 Dec 15;9:147. doi: 10.3389/fnmol.2016.00147. eCollection 2016.

9.

Novel roles of amyloid-beta precursor protein metabolites in fragile X syndrome and autism.

Westmark CJ, Sokol DK, Maloney B, Lahiri DK.

Mol Psychiatry. 2016 Oct;21(10):1333-41. doi: 10.1038/mp.2016.134. Epub 2016 Aug 30. Review.

10.

The quest for fragile X biomarkers.

Westmark CJ.

Mol Cell Pediatr. 2014 Dec;1(1):1. doi: 10.1186/s40348-014-0001-3. Epub 2014 Sep 4.

11.

Soy Infant Formula may be Associated with Autistic Behaviors.

Westmark CJ.

Autism Open Access. 2013 Nov 18;3. pii: 20727.

12.

A hypothesis regarding the molecular mechanism underlying dietary soy-induced effects on seizure propensity.

Westmark CJ.

Front Neurol. 2014 Sep 3;5:169. doi: 10.3389/fneur.2014.00169. eCollection 2014. Review.

13.

Soy infant formula and seizures in children with autism: a retrospective study.

Westmark CJ.

PLoS One. 2014 Mar 12;9(3):e80488. doi: 10.1371/journal.pone.0080488. eCollection 2014.

14.

Developing BACE-1 inhibitors for FXS.

Westmark CJ, Berry-Kravis EM, Ikonomidou C, Yin JC, Puglielli L.

Front Cell Neurosci. 2013 May 28;7:77. doi: 10.3389/fncel.2013.00077. eCollection 2013.

15.

FMRP: a triple threat to PSD-95.

Westmark CJ.

Front Cell Neurosci. 2013 Apr 30;7:57. doi: 10.3389/fncel.2013.00057. eCollection 2013. No abstract available.

16.

Soy-based diet exacerbates seizures in mouse models of neurological disease.

Westmark CJ, Westmark PR, Malter JS.

J Alzheimers Dis. 2013;33(3):797-805. doi: 10.3233/JAD-2012-121426.

17.

Recent progress in understanding plasticity in neurogenetic disorders.

Wang H, Westmark CJ, Frost E, Doering LC.

Neural Plast. 2012;2012:812472. doi: 10.1155/2012/812472. Epub 2012 Aug 28. No abstract available.

18.

What's hAPPening at synapses? The role of amyloid β-protein precursor and β-amyloid in neurological disorders.

Westmark CJ.

Mol Psychiatry. 2013 Apr;18(4):425-34. doi: 10.1038/mp.2012.122. Epub 2012 Aug 28. Review.

PMID:
22925831
19.

The regulation of AβPP expression by RNA-binding proteins.

Westmark CJ, Malter JS.

Ageing Res Rev. 2012 Sep;11(4):450-9. doi: 10.1016/j.arr.2012.03.005. Epub 2012 Apr 5. Review.

20.

Time of day regulates subcellular trafficking, tripartite synaptic localization, and polyadenylation of the astrocytic Fabp7 mRNA.

Gerstner JR, Vanderheyden WM, LaVaute T, Westmark CJ, Rouhana L, Pack AI, Wickens M, Landry CF.

J Neurosci. 2012 Jan 25;32(4):1383-94. doi: 10.1523/JNEUROSCI.3228-11.2012.

21.

Reversal of fragile X phenotypes by manipulation of AβPP/Aβ levels in Fmr1KO mice.

Westmark CJ, Westmark PR, O'Riordan KJ, Ray BC, Hervey CM, Salamat MS, Abozeid SH, Stein KM, Stodola LA, Tranfaglia M, Burger C, Berry-Kravis EM, Malter JS.

PLoS One. 2011;6(10):e26549. doi: 10.1371/journal.pone.0026549. Epub 2011 Oct 26.

22.

Preparation of synaptoneurosomes from mouse cortex using a discontinuous percoll-sucrose density gradient.

Westmark PR, Westmark CJ, Jeevananthan A, Malter JS.

J Vis Exp. 2011 Sep 17;(55). pii: 3196. doi: 10.3791/3196.

23.

Effect of Anticoagulants on Amyloid β-Protein Precursor and Amyloid Beta Levels in Plasma.

Westmark CJ, Hervey CM, Berry-Kravis EM, Malter JS.

J Alzheimers Dis Parkinsonism. 2011 Jul 24;1:101.

24.

Alzheimer's disease and Down syndrome rodent models exhibit audiogenic seizures.

Westmark CJ, Westmark PR, Malter JS.

J Alzheimers Dis. 2010;20(4):1009-13. doi: 10.3233/JAD-2010-100087.

25.

Pin1 and PKMzeta sequentially control dendritic protein synthesis.

Westmark PR, Westmark CJ, Wang S, Levenson J, O'Riordan KJ, Burger C, Malter JS.

Sci Signal. 2010 Mar 9;3(112):ra18. doi: 10.1126/scisignal.2000451.

26.

Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid.

Malter JS, Ray BC, Westmark PR, Westmark CJ.

Curr Alzheimer Res. 2010 May;7(3):200-6. Review.

27.

MPEP reduces seizure severity in Fmr-1 KO mice over expressing human Abeta.

Westmark CJ, Westmark PR, Malter JS.

Int J Clin Exp Pathol. 2009 Oct 10;3(1):56-68.

28.

Seizure susceptibility and mortality in mice that over-express amyloid precursor protein.

Westmark CJ, Westmark PR, Beard AM, Hildebrandt SM, Malter JS.

Int J Clin Exp Pathol. 2008 Jan 1;1(2):157-68.

29.

Thymic stromal lymphopoietin expression in allergic pulmonary inflammation is Pin1-dependent.

Esnault S, Rosenthal LA, Shen ZJ, Westmark CJ, Sorkness RL, Malter JS.

J Allergy Clin Immunol. 2008 May;121(5):1289-90. doi: 10.1016/j.jaci.2008.02.016. Epub 2008 Apr 18. No abstract available.

30.
31.

Decoy mRNAs reduce beta-amyloid precursor protein mRNA in neuronal cells.

Westmark PR, Shin HC, Westmark CJ, Soltaninassab SR, Reinke EK, Malter JS.

Neurobiol Aging. 2006 Jun;27(6):787-96. Epub 2006 May 2.

PMID:
16672170
32.

HuR mRNA ligands expressed after seizure.

Westmark CJ, Gourronc FA, Bartleson VB, Sayin U, Bhattacharya S, Sutula T, Malter JS.

J Neuropathol Exp Neurol. 2005 Dec;64(12):1037-45.

PMID:
16319714
33.

RhoB mRNA is stabilized by HuR after UV light.

Westmark CJ, Bartleson VB, Malter JS.

Oncogene. 2005 Jan 13;24(3):502-11.

PMID:
15543229
34.

Phosphorylation of Xenopus transcription factor IIIA by an oocyte protein kinase CK2.

Westmark CJ, Ghose R, Huber PW.

Biochem J. 2002 Mar 1;362(Pt 2):375-82.

35.

Extracellular-regulated kinase controls beta-amyloid precursor protein mRNA decay.

Westmark CJ, Malter JS.

Brain Res Mol Brain Res. 2001 Jun 20;90(2):193-201.

PMID:
11406297
36.
37.

Inhibition of RNA polymerase III transcription by a ribosome-associated kinase activity.

Westmark CJ, Ghose R, Huber PW.

Nucleic Acids Res. 1998 Oct 15;26(20):4758-64.

38.

hnRNP C increases amyloid precursor protein (APP) production by stabilizing APP mRNA.

Rajagopalan LE, Westmark CJ, Jarzembowski JA, Malter JS.

Nucleic Acids Res. 1998 Jul 15;26(14):3418-23.

Supplemental Content

Loading ...
Support Center